Advertisement

Current Stem Cell Reports

, Volume 4, Issue 1, pp 39–45 | Cite as

Hurdles Associated with the Translational Use of Genetically Modified Cells

  • Sunil S. Raikar
  • H. Trent Spencer
Stem Cells: Policies from the Bench to the Clinic (HT Spencer, Section Editor)
  • 47 Downloads
Part of the following topical collections:
  1. Topical Collection on Stem Cells: Policies from the Bench to the Clinic

Abstract

Purpose of Review

Recent advancements in the use of genetically modified hematopoietic stem cells (HSCs) and the emergent use of chimeric antigen receptor (CAR) T cell immunotherapy has highlighted issues associated with the use of genetically engineered cellular products. This review explores some of the challenges linked with translating the use of genetically modified cells.

Recent Findings

The use of genetically modified HSCs for ADA-SCID now has European approval and the U.S. Food and Drug Administration recently approved the use of CAR T cells for relapsed/refractory B cell acute lymphoblastic leukemia. Current good manufacturing processes have now been developed for the collection, expansion, storage, modification, and administration of genetically modified cells.

Summary

Genetically engineered cells can be used for several therapeutic purposes. However, significant challenges remain in making these cellular therapeutics readily available. A better understanding of this technology along with improvements in the manufacturing process is allowing the translation process to become more standardized.

Keywords

Lentiviral vector Transduction of hematopoietic stem cells Chimeric antigen receptor Genetic engineering 

Notes

Compliance with Ethical Standards

Conflict of Interest

Sunil S. Raikar and H. Trent Spencer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cicalese MP, Aiuti A. Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther. 2015;26(4):210–9.  https://doi.org/10.1089/hum.2015.047.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ferrari G, Cavazzana M, Mavilio F. Gene therapy approaches to hemoglobinopathies. Hematol Oncol Clin North Am. 2017;31(5):835–52.  https://doi.org/10.1016/j.hoc.2017.06.010.CrossRefPubMedGoogle Scholar
  3. 3.
    Penati R, Fumagalli F, Calbi V, Bernardo ME, Aiuti A. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis. 2017;40(4):543–54.  https://doi.org/10.1007/s10545-017-0052-4.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724–40.  https://doi.org/10.1016/j.cell.2017.01.016.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    •• Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185–93. Hematopoietic stem cells were among the first successful targets for gene addition, as described in this article. CrossRefPubMedGoogle Scholar
  6. 6.
    •• Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–55. This is the first published case of a patient with sickle cell disease being successfully treated with genetically modified autologous hematopoetic stem cells. CrossRefPubMedGoogle Scholar
  7. 7.
    •• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33. This describes the successful clinical use of chimeric antigen recepter-modifed T cells. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.  https://doi.org/10.1126/scitranslmed.3002842.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.  https://doi.org/10.1056/NEJMoa1407222.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    • Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. This is one of the first clinical trials that used autologous T cells genetically modified to express CD19-directed chimeric antigen receptors to treat patients with relapsed/refractory B cell acute lymphoblastic leukemia. CrossRefPubMedGoogle Scholar
  12. 12.
    • Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.  https://doi.org/10.1016/j.omtm.2016.12.006. A comprehensive overview of how CAR T cells are manufactured. CrossRefPubMedGoogle Scholar
  13. 13.
    de Wilde S, Guchelaar HJ, Zandvliet ML, Meij P. Understanding clinical development of chimeric antigen receptor T cell therapies. Cytotherapy. 2017;19(6):703–9.  https://doi.org/10.1016/j.jcyt.2017.03.070.CrossRefPubMedGoogle Scholar
  14. 14.
    McGuirk J, Waller EK, Qayed M, Abhyankar S, Ericson S, Holman P, et al. Building blocks for institutional preparation of CTL019 delivery. Cytotherapy. 2017;19(9):1015–24.  https://doi.org/10.1016/j.jcyt.2017.06.001.CrossRefPubMedGoogle Scholar
  15. 15.
    Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769–81.  https://doi.org/10.1016/j.ymthe.2017.06.012.CrossRefPubMedGoogle Scholar
  16. 16.
    Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG. Prospects for chimeric antigen receptor (CAR) gammadelta T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 2016;380(2):413–23.  https://doi.org/10.1016/j.canlet.2016.07.001.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284.  https://doi.org/10.1002/jca.21276.CrossRefPubMedGoogle Scholar
  18. 18.
    Li Y, Li J, Reeves HM, Reyes R, Maitta RW. Comparison of two apheresis systems during hematopoietic progenitor stem cell collections at a tertiary medical center. Transfusion. 2016;56(11):2833–8.  https://doi.org/10.1111/trf.13754.CrossRefPubMedGoogle Scholar
  19. 19.
    Lee SN, Sohn JY, Kong JH, Eom HS, Lee H, Kong SY. Comparison of two apheresis systems of COBE and Optia for autologous peripheral blood stem cell collection. Ann Lab Med. 2017;37(4):327–30.  https://doi.org/10.3343/alm.2017.37.4.327.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Even-Or E, Eden-Walker A, Di Mola M, McDougall E, Schechter T, Ali M, et al. Comparison of two apheresis systems for autologous stem cell collections in pediatric oncology patients. Transfusion. 2017;57(1):122–30.  https://doi.org/10.1111/trf.13859.CrossRefPubMedGoogle Scholar
  21. 21.
    Deneys V, Fabry A, Van Hooydonk M, Sonet A, Andre M, Bourgeois M, et al. Efficiency of autologous stem cell collection: comparison of three different cell separators. Transfus Apher Sci. 2017;56(1):35–8.  https://doi.org/10.1016/j.transci.2016.12.015.CrossRefPubMedGoogle Scholar
  22. 22.
    Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22(2):79–84.  https://doi.org/10.1038/cgt.2015.5.CrossRefPubMedGoogle Scholar
  23. 23.
    Powell DJ Jr, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy. 2009;11(7):923–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Grosse J, Meier K, Bauer TJ, Eilles C, Grimm D. Cell separation by countercurrent centrifugal elutriation: recent developments. Prep Biochem Biotechnol. 2012;42(3):217–33.  https://doi.org/10.1080/10826068.2011.602799.CrossRefPubMedGoogle Scholar
  25. 25.
    Kara A, Turgut S, Cagli A, Sahin F, Oran E, Tunc B. Complications of therapeutic apheresis in children. Transfus Apher Sci. 2013;48(3):375–6.  https://doi.org/10.1016/j.transci.2013.04.020.CrossRefPubMedGoogle Scholar
  26. 26.
    Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. Int J Hematol. 2017;105(2):141–52.  https://doi.org/10.1007/s12185-016-2156-2.CrossRefPubMedGoogle Scholar
  27. 27.
    Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262–73.  https://doi.org/10.1016/j.bbmt.2014.05.003.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim JV, Latouche JB, Riviere I, Sadelain M. The ABCs of artificial antigen presentation. Nat Biotechnol. 2004;22(4):403–10.  https://doi.org/10.1038/nbt955.CrossRefPubMedGoogle Scholar
  29. 29.
    Neurauter AA, Bonyhadi M, Lien E, Nokleby L, Ruud E, Camacho S, et al. Cell isolation and expansion using Dynabeads. Adv Biochem Eng Biotechnol. 2007;106:41–73.PubMedGoogle Scholar
  30. 30.
    Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010–7.  https://doi.org/10.1158/0008-5472.CAN-08-3712.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008;10(8):842–56.  https://doi.org/10.1080/14653240802419328.CrossRefPubMedGoogle Scholar
  32. 32.
    Froud SJ. The development, benefits and disadvantages of serum-free media. Dev Biol Stand. 1999;99:157–66.PubMedGoogle Scholar
  33. 33.
    • Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 2017;19(2):155–69. This review describes the state of the art usefulness of serum-free media. CrossRefPubMedGoogle Scholar
  34. 34.
    McGillicuddy N, Floris P, Albrecht S, Bones J. Examining the sources of variability in cell culture media used for biopharmaceutical production. Biotechnol Lett. 2017;  https://doi.org/10.1007/s10529-017-2437-8.
  35. 35.
    Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, et al. A rapid cell expansion process for production of engineered autologous CAR-T cell therapies. Hum Gene Ther Methods. 2016;27(6):209–18.  https://doi.org/10.1089/hgtb.2016.120.CrossRefPubMedGoogle Scholar
  36. 36.
    Sutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT. Bioengineering and serum free expansion of blood-derived γδ T cells. Cytotherapy. 2016;18(7):881–92.  https://doi.org/10.1016/j.jcyt.2016.04.001.CrossRefPubMedGoogle Scholar
  37. 37.
    Booth C, Gaspar HB, Thrasher AJ. Treating immunodeficiency through HSC gene therapy. Trends Mol Med. 2016;22(4):317–27.  https://doi.org/10.1016/j.molmed.2016.02.002.CrossRefPubMedGoogle Scholar
  38. 38.
    Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17(1):63–89.  https://doi.org/10.1146/annurev-bioeng-071813-104938.CrossRefPubMedGoogle Scholar
  39. 39.
    Chira S, Jackson CS, Oprea I, Ozturk F, Pepper MS, Diaconu I, et al. Progresses towards safe and efficient gene therapy vectors. Oncotarget. 2015;6(31):30675–703.  https://doi.org/10.18632/oncotarget.5169.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Demeulemeester J, De Rijck J, Gijsbers R, Debyser Z. Retroviral integration: site matters: mechanisms and consequences of retroviral integration site selection. BioEssays. 2015;37(11):1202–14.  https://doi.org/10.1002/bies.201500051.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Schweizer M, Merten OW. Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther. 2010;10(6):474–86.  https://doi.org/10.2174/156652310793797748.CrossRefPubMedGoogle Scholar
  42. 42.
    McCarron A, Donnelley M, McIntyre C, Parsons D. Challenges of up-scaling lentivirus production and processing. J Biotechnol. 2016;240:23–30.  https://doi.org/10.1016/j.jbiotec.2016.10.016.CrossRefPubMedGoogle Scholar
  43. 43.
    Merten OW, Hebben M, Bovolenta C. Production of lentiviral vectors. Mol Ther Methods Clin Dev. 2016;3:16017.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Kiem HP, Baum C, Bushman FD, Byrne BJ, Carter BJ, Cavagnaro J, et al. Charting a clear path: the ASGCT standardized pathways conference. Mol Ther. 2014;22(7):1235–8.  https://doi.org/10.1038/mt.2014.95.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 2006;108(8):2545–53.  https://doi.org/10.1182/blood-2005-08-024976.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009;17(11):1919–28.  https://doi.org/10.1038/mt.2009.179.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor. J Transl Med. 2012;10(1):69.  https://doi.org/10.1186/1479-5876-10-69.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Somerville RP, Dudley ME. Bioreactors get personal. Oncoimmunology. 2012;1(8):1435–7.  https://doi.org/10.4161/onci.21206.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Sadeghi A, Pauler L, Anneren C, Friberg A, Brandhorst D, Korsgren O, et al. Large-scale bioreactor expansion of tumor-infiltrating lymphocytes. J Immunol Methods. 2011;364(1–2):94–100.  https://doi.org/10.1016/j.jim.2010.11.007.CrossRefPubMedGoogle Scholar
  50. 50.
    Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169–80.  https://doi.org/10.1097/CJI.0b013e318194a6e8.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Donia M, Larsen SM, Met O, Svane IM. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the wave bioreactor. Cytotherapy. 2014;16(8):1117–20.  https://doi.org/10.1016/j.jcyt.2014.02.004.CrossRefPubMedGoogle Scholar
  52. 52.
    Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, et al. Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev. 2014;1:14015.  https://doi.org/10.1038/mtm.2014.15.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012;14(9):1131–43.  https://doi.org/10.3109/14653249.2012.700767.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Kaiser AD, Assenmacher M, Schroder B, Meyer M, Orentas R, Bethke U, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 2015;22(2):72–8.  https://doi.org/10.1038/cgt.2014.78.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Spohn G, Wiercinska E, Karpova D, Bunos M, Hummer C, Wingenfeld E, et al. Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy. 2015;17(10):1465–71.  https://doi.org/10.1016/j.jcyt.2015.04.005.CrossRefPubMedGoogle Scholar
  56. 56.
    Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston IC, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy. 2016;18(8):1002–11.  https://doi.org/10.1016/j.jcyt.2016.05.009.CrossRefPubMedGoogle Scholar
  57. 57.
    Hunt EA, Jain NG, Somers MJ. Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease. J Clin Apher. 2013;28(1):36–47.  https://doi.org/10.1002/jca.21260.CrossRefPubMedGoogle Scholar
  58. 58.
    Xie J, Zhang C. Ex vivo expansion of hematopoietic stem cells. Sci China Life Sci. 2015;58(9):839–53.  https://doi.org/10.1007/s11427-015-4895-3.CrossRefPubMedGoogle Scholar
  59. 59.
    Brooks R, Iyer S, Akada H, Neelam S, Russo CM, Chisholm JD, et al. Coordinate expansion of murine hematopoietic and mesenchymal stem cell compartments by SHIPi. Stem Cells. 2015;33(3):848–58.  https://doi.org/10.1002/stem.1902.CrossRefPubMedGoogle Scholar
  60. 60.
    Wang L, Guan X, Wang H, Shen B, Zhang Y, Ren Z, et al. A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation. Stem Cell Res Ther. 2017;8(1):169.  https://doi.org/10.1186/s13287-017-0625-z.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Zonari E, Desantis G, Petrillo C, Boccalatte FE, Lidonnici MR, Kajaste-Rudnitski A, et al. Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy. Stem Cell Rep. 2017;8(4):977–90.  https://doi.org/10.1016/j.stemcr.2017.02.010.CrossRefGoogle Scholar
  62. 62.
    Zhao Y, Stepto H, Schneider CK. Development of the first World Health Organization lentiviral vector standard: toward the production control and standardization of lentivirus-based gene therapy products. Hum Gene Ther Methods. 2017;28(4):205–14.  https://doi.org/10.1089/hgtb.2017.078.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Stefan Radtke JA, Morgan Giese, Yan-Yi Chan, Zachary Norgaard, Mark Enstrom, Kevin Haworth, Lauren Schefter, Hans-Peter Kiem. A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates. Sci Transl Med. 2017;9(414).Google Scholar
  64. 64.
    Hacein-Bey Abina S, Gaspar HB, Blondeau J, Caccavelli L, Charrier S, Buckland K, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015;313(15):1550–63.  https://doi.org/10.1001/jama.2015.3253.CrossRefPubMedGoogle Scholar
  65. 65.
    Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J. 2014;20(2):141–4.  https://doi.org/10.1097/PPO.0000000000000036.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–31.  https://doi.org/10.1182/blood-2017-02-769208.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Lecchi L, Giovanelli S, Gagliardi B, Pezzali I, Ratti I, Marconi M. An update on methods for cryopreservation and thawing of hemopoietic stem cells. Transfus Apher Sci. 2016;54(3):324–36.  https://doi.org/10.1016/j.transci.2016.05.009.CrossRefPubMedGoogle Scholar
  68. 68.
    Spoerl S, Peter R, Krackhardt AM. Cryopreservation in closed bag systems as an alternative to clean rooms for preparations of peripheral blood stem cells. Adv Exp Med Biol. 2016;951:67–76.  https://doi.org/10.1007/978-3-319-45457-3_6.CrossRefPubMedGoogle Scholar
  69. 69.
    Otrock ZK, Sempek DS, Carey S, Grossman BJ. Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study. Transfusion. 2017;57(6):1522–6.  https://doi.org/10.1111/trf.14072.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cell and Gene Therapy Program, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory Children’s CenterEmory University School of MedicineAtlantaUSA

Personalised recommendations